Table 2 Number of cases, incidence rates of all-cause mortality, emergency department visits, and unscheduled hospitalizations after second dose of BNT162b2 and CoronaVac
Event | Before weighting | After weighting | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Recommended (N = 654,900) | Delayed (N = 116,880) | Delayed vs recommended interval | |||||||||||
Cumulative incidence | Crude incidence rate (events/10,000 person-days) | Cumulative incidence | Crude incidence rate (events/10,000 person-days) | HRa | 95% CI | P-value | |||||||
Cases with event | Rate | Estimate | 95% CI | Person-days | Cases with event | Rate | Estimate | 95% CI | Person-days | ||||
Mortality after second dose | |||||||||||||
  BNT162b2 | 15 | 0.0037% | 0.0133 | (0.01, 0.02) | 11,241,070 | 2 | 0.0125% | 0.0446 | (0.01, 0.16) | 448,656 | 4.438 | (0.951, 20.701) | 0.058 |
 CoronaVac | 16 | 0.0063% | 0.0225 | (0.01, 0.04) | 7,095,767 | 7 | 0.0069% | 0.0248 | (0.01, 0.05) | 2,823,889 | 1.185 | (0.478, 2.937) | 0.714 |
ED visit after second dose | |||||||||||||
  BNT162b2 | 13,818 | 3.44% | 12.55 | (12.34, 12.76) | 11,011,002 | 635 | 3.96% | 14.49 | (13.38, 15.66) | 438,314 | 1.037 | (0.951, 1.130) | 0.411 |
  CoronaVac | 7856 | 3.10% | 11.26 | (11.01, 11.51) | 6,977,752 | 3112 | 3.09% | 11.21 | (10.82, 11.61) | 2,776,922 | 0.966 | (0.926, 1.008) | 0.113 |
Unscheduled hospitalization after second dose | |||||||||||||
  BNT162b2 | 2929 | 0.73% | 2.62 | (2.52, 2.71) | 11,195,142 | 124 | 0.77% | 2.78 | (2.31, 3.31) | 446,704 | 1.054 | (0.867, 1.281) | 0.597 |
  CoronaVac | 2068 | 0.82% | 2.93 | (2.80, 3.06) | 7,065,542 | 781 | 0.77% | 2.78 | (2.59, 2.98) | 2,812,393 | 0.956 | (0.878, 1.040) | 0.294 |